All In Biotech

Drug Trial Radar · NCT07608432

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of DYNE-251 Administered Intravenously in Ambulatory Male Participants 4 to 18 Years of Age With Duchenne Muscular Dystrophy Amenable to Exon-51 Skipping

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Dec 2030

Study completion Oct 2032

Sponsor

Lead sponsor
Dyne TherapeuticsIndustry
Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.

Conditions

  • Duchenne Muscular Dystrophy (DMD)
  • Muscular Dystrophy, Duchenne
  • Muscular Dystrophy (DMD)
  • DMD
  • Muscular Dystrophies
  • Muscular Dystrophy in Children
  • Muscular Dystrophy, Duchenne Type
  • Muscular Dystrophy, Duchenne and Becker Types
  • Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
  • Genetic Disease, Inborn
  • Genetic Disease, X-Linked
  • Congenital, Hereditary, and Neonatal Diseases and Abnormalities
  • Neuromuscular Diseases (NMD)

Interventions

  • Zeleciment Rostudirsen (DYNE-251)Drug

    Administered by IV infusion

  • PlaceboDrug

    Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rise From Floor (RFF) velocityTime frame: Baseline, Week 73

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rare Disease Research, LLC

    Hillsborough, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.